<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04073368</url>
  </required_header>
  <id_info>
    <org_study_id>AXA1125-003</org_study_id>
    <nct_id>NCT04073368</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)</brief_title>
  <official_title>A 16-Week, Single-Blind Randomized, Placebo- Controlled Food Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axcella Health, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axcella Health, Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, single blind study to determine whether AXA1125 or AXA1957, novel
      compositions of amino acids, are safe and well tolerated. Subjects have non-alcoholic fatty
      liver disease (NAFLD) and the study will also examine liver biology using blood tests and
      magnetic resonance imaging (MRI).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 3, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of study product emergent adverse events (AEs)and serious adverse events (SAEs)</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>AEs and SAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in liver fat as assessed by MRI-PDFF</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>MRI-PDFF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HOMA-IR</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>HOMA-IR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma glucose</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>Primary glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma insulin</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>Plasma Insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in alanine aminotransferase (ALT)</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>ALT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in aspartate aminotransferase (AST)</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>AST</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>AXA1957 high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AXA1957 20.3g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AXA1957 low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AXA1957 13.5g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AXA1125</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AXA1125 24g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 24g</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>AXA1957</intervention_name>
    <description>Amino acids, food study</description>
    <arm_group_label>AXA1957 high dose</arm_group_label>
    <arm_group_label>AXA1957 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>AXA1125</intervention_name>
    <description>Amino acids, food study</description>
    <arm_group_label>AXA1125</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Amino acids, food study</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Willing to participate in the study and provide written informed consent.

          -  Male and female adults aged &gt; 18 years.

          -  Subjects must not have participated in any diet/lifestyle intervention or
             observational studies, or engaged in any body weight altering regimens that resulted
             in body weight fluctuations (i.e. body weight loss or gain by 5%) in the preceding 3
             months prior to Screening.

          -  A screening MRI consistent with liver inflammation and fibrosis.

        Key Exclusion Criteria:

          -  Current or history of significant alcohol consumption.

          -  History or presence of liver disease (other than NAFLD/NASH).

          -  History or presence of cirrhosis and/or history or presence of hepatic decompensation.

          -  Any diabetes other than Type 2.

          -  Other poorly controlled medical condition (for example, uncontrolled hypertension with
             a systolic blood pressure &gt; 100 mmHg).

          -  Known sensitivity and/or history of clinically significant food intolerance/allergies
             to proteins (including whey, soy, casein, amino acids, etc.).

          -  Unable or unwilling to adhere to contraception requirements.

          -  Any contraindications to a MRI scan.

          -  Any other condition that, in the opinion of the Investigator, renders the subject at
             risk for compliance, compromises the well-being of the subject, or hinders study
             completion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Harrison, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pinnacle Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Institute for Liver Health LLC</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Institute for Liver Health LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85641</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Wilshire</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catalina Research Institute, LLC</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Panorama</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excel Medical Clinical Trials, LLC</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33427</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Digestive Health Specialists</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research, LLC - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioclinica Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Therapy and Advanced Research LLC</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro One</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>20874</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>73301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Center of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors Hospital at Renaissance, LLC</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants (TDDC) - Downtown Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 27, 2019</study_first_submitted>
  <study_first_submitted_qc>August 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

